Pharma Focus Europe

Bavarian Nordic Enters Agreement with Country in Latin America on the Supply of Monkeypox Vaccines

Tuesday, October 04, 2022

Bavarian Nordic A/S announced an agreement with a Latin American country for the supply of the Company’s monkeypox vaccine. This is the Company’s first bilateral supply agreement for the vaccine in Latin America, outside the scope of the agreement entered with the Pan American Health Organization (PAHO) in August 2022, which has enabled access to the vaccine for its member countries.

Through PAHO’s Revolving Fund for Access to Vaccines, the country will get access to its first monkeypox vaccines later this month and deliveries under the bilateral agreement will start in December 2022.

Separately, following the initial supply agreement in August, PAHO has requested additional doses to be delivered before year-end to expand access for its member countries.

Paul Chaplin, President and CEO of Bavarian Nordic said: “Vaccinating against monkeypox has been a key element in tackling the outbreak and we are extremely pleased to reinforce our commitment to the region and increase the availability of our vaccine through additional supply agreements.”

Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024